DK2877165T3 - Forbedret hjerne biotilgængelighed af galantamin ved udvalgte formuleringer og transmukosal administration af lipofil prodrug - Google Patents
Forbedret hjerne biotilgængelighed af galantamin ved udvalgte formuleringer og transmukosal administration af lipofil prodrug Download PDFInfo
- Publication number
- DK2877165T3 DK2877165T3 DK13745810.5T DK13745810T DK2877165T3 DK 2877165 T3 DK2877165 T3 DK 2877165T3 DK 13745810 T DK13745810 T DK 13745810T DK 2877165 T3 DK2877165 T3 DK 2877165T3
- Authority
- DK
- Denmark
- Prior art keywords
- galantamine
- transmucosal administration
- selected formulations
- improved brain
- lipophilic prodrug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261676348P | 2012-07-27 | 2012-07-27 | |
| EP12178187 | 2012-07-27 | ||
| PCT/EP2013/065880 WO2014016430A1 (en) | 2012-07-27 | 2013-07-29 | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2877165T3 true DK2877165T3 (da) | 2019-01-02 |
Family
ID=49996636
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18186075.0T DK3417862T3 (da) | 2012-07-27 | 2013-07-29 | Forbedret hjerne biotilgængelighed af galantamin ved udvalgte formuleringer og transmucosal administration af lipofile prodrugs |
| DK13745810.5T DK2877165T3 (da) | 2012-07-27 | 2013-07-29 | Forbedret hjerne biotilgængelighed af galantamin ved udvalgte formuleringer og transmukosal administration af lipofil prodrug |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18186075.0T DK3417862T3 (da) | 2012-07-27 | 2013-07-29 | Forbedret hjerne biotilgængelighed af galantamin ved udvalgte formuleringer og transmucosal administration af lipofile prodrugs |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150190401A1 (da) |
| EP (2) | EP2877165B1 (da) |
| JP (2) | JP6272857B2 (da) |
| CN (2) | CN104507461A (da) |
| AU (1) | AU2013294917B2 (da) |
| CA (1) | CA2878135C (da) |
| DK (2) | DK3417862T3 (da) |
| ES (1) | ES2700473T3 (da) |
| HK (1) | HK1206242A1 (da) |
| IN (1) | IN2015DN00229A (da) |
| PL (2) | PL3417862T3 (da) |
| WO (1) | WO2014016430A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090253654A1 (en) | 2005-09-22 | 2009-10-08 | Galantos Pharma Gmbh | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
| CA2878135C (en) * | 2012-07-27 | 2019-12-03 | Neurodyn Life Sciences Inc. | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
| JP6906955B2 (ja) | 2014-05-16 | 2021-07-21 | シナプテック・ディヴェロップメント・エルエルシーＳｙｎａｐｔｅｃ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｌｃ | 認知症の症状が観察されない患者の認知症の発症を遅らせるための薬剤 |
| JP2020033304A (ja) * | 2018-08-30 | 2020-03-05 | 医療法人ふじいやさか | 薬剤又はサプリメント、組成物、及び水素供給器の使用 |
| EP4029867A1 (en) * | 2021-01-13 | 2022-07-20 | Alpha Cognition Inc. | Solid forms of galantamine benzoate gluconate |
| EP4337218A1 (en) * | 2021-05-14 | 2024-03-20 | Alpha Cognition Inc. | Self-preserving compositions and multi-use dispensers for administering alpha-1062 |
| EP4186509A1 (en) | 2021-11-26 | 2023-05-31 | Alpha Cognition Inc. | Alpha-1062 for treating traumatic brain injury |
| CA3238221A1 (en) * | 2021-11-26 | 2023-06-01 | Alpha Cognition Inc. | Alpha-1062 for treating traumatic brain injury |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1248059B (it) * | 1991-06-14 | 1995-01-05 | Miat Spa | Insufflatore multidose per farmaci in polvere |
| CA2460118A1 (en) * | 2001-10-31 | 2003-05-08 | Pfizer Products Inc. | Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome |
| US20040254146A1 (en) * | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| JP2009508903A (ja) * | 2005-09-22 | 2009-03-05 | ガラントス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 認知障害を伴う疾患の治療に用いるための脳血液関門透過性が改善されたコリン作用増強剤 |
| US20090253654A1 (en) * | 2005-09-22 | 2009-10-08 | Galantos Pharma Gmbh | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
| US9808509B2 (en) * | 2007-06-08 | 2017-11-07 | Healthpartners Research Foundation | Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system |
| MX2010011032A (es) * | 2008-04-11 | 2011-03-01 | Cytotech Labs Llc Star | Metodos y uso de induccion de apoptosis en celulas cancerigenas. |
| EP2137192B8 (en) * | 2008-04-14 | 2014-06-11 | Neurodyn Life Sciences Inc. | Derivatives of galantamine as pro-drugs for the treatment of human brain diseases |
| US20130317117A1 (en) * | 2010-11-24 | 2013-11-28 | Pharmaceutics International, Inc. | Self micro-emulsifying drug delivery system with increased bioavailability |
| CA2878135C (en) * | 2012-07-27 | 2019-12-03 | Neurodyn Life Sciences Inc. | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
-
2013
- 2013-07-29 CA CA2878135A patent/CA2878135C/en active Active
- 2013-07-29 PL PL18186075T patent/PL3417862T3/pl unknown
- 2013-07-29 US US14/417,502 patent/US20150190401A1/en not_active Abandoned
- 2013-07-29 JP JP2015523573A patent/JP6272857B2/ja active Active
- 2013-07-29 CN CN201380039870.3A patent/CN104507461A/zh active Pending
- 2013-07-29 DK DK18186075.0T patent/DK3417862T3/da active
- 2013-07-29 PL PL13745810T patent/PL2877165T3/pl unknown
- 2013-07-29 EP EP13745810.5A patent/EP2877165B1/en active Active
- 2013-07-29 EP EP18186075.0A patent/EP3417862B1/en active Active
- 2013-07-29 AU AU2013294917A patent/AU2013294917B2/en active Active
- 2013-07-29 WO PCT/EP2013/065880 patent/WO2014016430A1/en active Application Filing
- 2013-07-29 CN CN201810140325.8A patent/CN108245522A/zh active Pending
- 2013-07-29 DK DK13745810.5T patent/DK2877165T3/da active
- 2013-07-29 ES ES13745810T patent/ES2700473T3/es active Active
-
2015
- 2015-01-09 IN IN229DEN2015 patent/IN2015DN00229A/en unknown
- 2015-07-16 HK HK15106777.9A patent/HK1206242A1/xx unknown
-
2018
- 2018-01-04 JP JP2018000060A patent/JP6574002B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2878135A1 (en) | 2014-01-30 |
| PL3417862T3 (pl) | 2021-11-22 |
| AU2013294917A1 (en) | 2015-01-22 |
| DK3417862T3 (da) | 2021-07-12 |
| IN2015DN00229A (da) | 2015-06-12 |
| CN104507461A (zh) | 2015-04-08 |
| HK1206242A1 (en) | 2016-01-08 |
| WO2014016430A1 (en) | 2014-01-30 |
| JP6574002B2 (ja) | 2019-09-11 |
| EP3417862A1 (en) | 2018-12-26 |
| PL2877165T3 (pl) | 2019-05-31 |
| CA2878135C (en) | 2019-12-03 |
| EP2877165A1 (en) | 2015-06-03 |
| JP2015524423A (ja) | 2015-08-24 |
| EP3417862B1 (en) | 2021-05-05 |
| US20150190401A1 (en) | 2015-07-09 |
| AU2013294917B2 (en) | 2016-12-15 |
| JP2018100272A (ja) | 2018-06-28 |
| CN108245522A (zh) | 2018-07-06 |
| JP6272857B2 (ja) | 2018-01-31 |
| EP2877165B1 (en) | 2018-09-05 |
| ES2700473T3 (es) | 2019-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2877165T3 (da) | Forbedret hjerne biotilgængelighed af galantamin ved udvalgte formuleringer og transmukosal administration af lipofil prodrug | |
| DK2968529T3 (da) | Fremstilling af jordnøddeformuleringer til oral desensibilisering | |
| DK3725778T3 (da) | Formuleringer af enzalutamid | |
| DK2812000T3 (da) | Flerlaget nikotinholdig farmaceutisk sammensætning | |
| DK2914248T4 (da) | Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme | |
| IL222406A0 (en) | Improved liposomal formulations of lipophilic compounds | |
| DK2895156T3 (da) | Fremgangsmåde til fremstilling af terapeutiske nanopartikler | |
| BR112013033885A2 (pt) | cápsula pré-embalada de material fumável | |
| DK3284467T3 (da) | Nikotinholdige farmaceutiske sammensætninger | |
| DK2872497T4 (da) | Chromanyl-derivater til behandling af mitokondriel sygdom | |
| DK3106150T3 (da) | Forbedrede farmaceutiske sammensætninger af pimobendan | |
| CO6940426A2 (es) | Formulaciones farmacéuticas | |
| DK2827862T3 (da) | Formuleringer af bendamustin | |
| DK2819648T3 (da) | Farmaceutisk præparat omfattende et antiviralt virksomt dihydroquinazolinderivat | |
| IL236465A0 (en) | Pharmaceutical composition for delayed release of active substances | |
| DK2644189T3 (da) | Stabile bortezomib-formuleringer | |
| HK1200106A1 (en) | Formulations for enhanced bioavailability of zanamivir | |
| BR112014018851A2 (pt) | melhoramento da estabilidade postural administrando droxidopa | |
| SG11201503051QA (en) | Formulations of pyrimidinedione derivative compounds | |
| SMT201600419B (it) | Composizione farmaceutica contenente fosfolipidi | |
| DK2877155T3 (da) | Opioidformuleringer | |
| CU24157B1 (es) | Composición farmacéutica de liberación prolongada de trimetazidina | |
| DK3251507T3 (da) | Forbedrede insekticidformuleringer | |
| DK2928896T3 (da) | Fast form af dihydro-pyrido-oxazin-derivat | |
| DK2884996T3 (da) | Immunogen sammensætning af dræbte leptospira-bakterier |